EUR 169.2
(5.0%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 6.56 Billion EUR | -3.53% |
2022 | 6.8 Billion EUR | 16.83% |
2021 | 5.82 Billion EUR | -3.69% |
2020 | 6.04 Billion EUR | 48.5% |
2019 | 4.07 Billion EUR | -4.39% |
2018 | 4.25 Billion EUR | 1.87% |
2017 | 4.18 Billion EUR | -11.7% |
2016 | 4.73 Billion EUR | -12.48% |
2015 | 5.41 Billion EUR | 2.89% |
2014 | 5.25 Billion EUR | -3.29% |
2013 | 5.43 Billion EUR | 14.05% |
2012 | 4.76 Billion EUR | 9.46% |
2011 | 4.35 Billion EUR | -0.5% |
2010 | 4.37 Billion EUR | -6.93% |
2009 | 4.7 Billion EUR | -14.6% |
2008 | 5.5 Billion EUR | 4.08% |
2007 | 5.29 Billion EUR | -7.5% |
2006 | 5.72 Billion EUR | 147.83% |
2005 | 2.3 Billion EUR | -32.29% |
2004 | 3.4 Billion EUR | 160.76% |
2003 | 1.3 Billion EUR | 23.83% |
2002 | 1.05 Billion EUR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 6.67 Billion EUR | 0.0% |
2023 FY | 6.56 Billion EUR | -3.53% |
2023 Q2 | 6.34 Billion EUR | 0.0% |
2023 Q4 | 6.56 Billion EUR | 0.0% |
2022 FY | 6.8 Billion EUR | 16.83% |
2022 Q2 | 7.39 Billion EUR | 0.0% |
2022 Q4 | 6.8 Billion EUR | 0.0% |
2021 Q2 | 5.36 Billion EUR | 0.0% |
2021 Q4 | 5.82 Billion EUR | 0.0% |
2021 FY | 5.82 Billion EUR | -3.69% |
2020 Q4 | 6.04 Billion EUR | 0.0% |
2020 Q2 | 6.12 Billion EUR | 0.0% |
2020 FY | 6.04 Billion EUR | 48.5% |
2019 Q4 | 4.07 Billion EUR | 0.0% |
2019 FY | 4.07 Billion EUR | -4.39% |
2019 Q2 | 4.06 Billion EUR | 0.0% |
2018 Q4 | 4.25 Billion EUR | 0.0% |
2018 FY | 4.25 Billion EUR | 1.87% |
2018 Q2 | 4.25 Billion EUR | 0.0% |
2017 FY | 4.18 Billion EUR | -11.7% |
2017 Q2 | 4.27 Billion EUR | 0.0% |
2017 Q4 | 4.18 Billion EUR | 0.0% |
2016 Q4 | 4.73 Billion EUR | 0.0% |
2016 FY | 4.73 Billion EUR | -12.48% |
2016 Q2 | 5.12 Billion EUR | 0.0% |
2015 Q4 | 5.41 Billion EUR | 0.0% |
2015 Q2 | 5.43 Billion EUR | 0.0% |
2015 FY | 5.41 Billion EUR | 2.89% |
2014 Q2 | 5.06 Billion EUR | 0.0% |
2014 FY | 5.25 Billion EUR | -3.29% |
2014 Q4 | 5.25 Billion EUR | 0.0% |
2013 Q4 | 5.3 Billion EUR | 0.0% |
2013 FY | 5.43 Billion EUR | 14.05% |
2013 Q2 | 5.06 Billion EUR | 0.0% |
2012 Q2 | 4.61 Billion EUR | 0.0% |
2012 FY | 4.76 Billion EUR | 9.46% |
2012 Q4 | 4.76 Billion EUR | 0.0% |
2011 Q4 | 4.35 Billion EUR | 0.0% |
2011 Q2 | 3.75 Billion EUR | 0.0% |
2011 FY | 4.35 Billion EUR | -0.5% |
2010 FY | 4.37 Billion EUR | -6.93% |
2010 Q4 | 4.37 Billion EUR | 0.0% |
2010 Q2 | 5.26 Billion EUR | 0.0% |
2009 Q4 | 4.7 Billion EUR | 0.0% |
2009 FY | 4.7 Billion EUR | -14.6% |
2008 FY | 5.5 Billion EUR | 4.08% |
2007 FY | 5.29 Billion EUR | -7.5% |
2006 FY | 5.72 Billion EUR | 147.83% |
2005 FY | 2.3 Billion EUR | -32.29% |
2004 FY | 3.4 Billion EUR | 160.76% |
2003 FY | 1.3 Billion EUR | 23.83% |
2002 FY | 1.05 Billion EUR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Nicox S.A. | 31.56 Million EUR | -20693.867% |
European Medical Solutions | 33.86 Million EUR | -19282.271% |
FERMENTALG | 19.39 Million EUR | -33738.54% |
argenx SE | 402.79 Million EUR | -1529.6% |
BioSenic S.A. | 32.26 Million EUR | -20244.657% |
Celyad Oncology SA | 9.97 Million EUR | -65684.726% |
Hyloris Pharmaceuticals SA | 8.61 Million EUR | -76119.229% |
Onward Medical N.V. | 25.69 Million EUR | -25442.844% |
Oxurion NV | 19.73 Million EUR | -33159.019% |
PHAXIAM Therapeutics S.A. | 25.69 Million EUR | -25445.826% |
Financière de Tubize SA | 123.65 Million EUR | -5208.526% |